Literature DB >> 31494187

DNA methyltransferases: emerging targets for the discovery of inhibitors as potent anticancer drugs.

Jie Yu1, Tianli Xie1, Zhe Wang1, Xuwen Wang1, Su Zeng1, Yu Kang2, Tingjun Hou3.   

Abstract

DNA methyltransferases (DNMTs) are a conserved family of cytosine methylases with crucial roles in epigenetic regulation. They have been considered as promising therapeutic targets for the epigenetic treatment of cancer. Therefore, DNMT inhibitors (DNMTis) have attracted considerable interest in recent years for the modulation of the aberrant DNA methylation pattern in a reversible way. In this review, we provide a structure-based overview of the therapeutic importance of DNMTs against different cancer types, and then summarize recently investigated DNMTis as well as their inhibitory mechanisms, focusing on recent advances in the development of DNMTis with specificity and/or selectivity using computational approaches.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31494187     DOI: 10.1016/j.drudis.2019.08.006

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  8 in total

1.  7-Aminoalkoxy-Quinazolines from Epigenetic Focused Libraries Are Potent and Selective Inhibitors of DNA Methyltransferase 1.

Authors:  José L Medina-Franco; Edgar López-López; Liliam P Martínez-Fernández
Journal:  Molecules       Date:  2022-04-30       Impact factor: 4.927

Review 2.  Small molecule targeting of chromatin writers in cancer.

Authors:  Andrew R Conery; Jennifer L Rocnik; Patrick Trojer
Journal:  Nat Chem Biol       Date:  2021-12-24       Impact factor: 15.040

3.  Expanding the Structural Diversity of DNA Methyltransferase Inhibitors.

Authors:  K Eurídice Juárez-Mercado; Fernando D Prieto-Martínez; Norberto Sánchez-Cruz; Andrea Peña-Castillo; Diego Prada-Gracia; José L Medina-Franco
Journal:  Pharmaceuticals (Basel)       Date:  2020-12-27

4.  The Cancer/Testis Antigen Gene VCX2 Is Rarely Expressed in Malignancies but Can Be Epigenetically Activated Using DNA Methyltransferase and Histone Deacetylase Inhibitors.

Authors:  Mie K Jakobsen; Sofie Traynor; Mette Stæhr; Pascal G Duijf; Aaraby Y Nielsen; Mikkel G Terp; Christina B Pedersen; Per Guldberg; Henrik J Ditzel; Morten F Gjerstorff
Journal:  Front Oncol       Date:  2021-02-09       Impact factor: 6.244

Review 5.  Recent Clinical Update of Acute Myeloid Leukemia: Focus on Epigenetic Therapies.

Authors:  Eunyoung Lee; Youngil Koh; Junshik Hong; Hyeon Seok Eom; Sung Soo Yoon
Journal:  J Korean Med Sci       Date:  2021-04-05       Impact factor: 2.153

6.  Elevated BICD2 DNA methylation in blood of major depressive disorder patients and reduction of depressive-like behaviors in hippocampal Bicd2-knockdown mice.

Authors:  Jianbo Xiu; Jiayu Li; Zeyue Liu; Hui Wei; Caiyun Zhu; Rongrong Han; Zijing Liu; Wanwan Zhu; Yan Shen; Qi Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-18       Impact factor: 12.779

Review 7.  The Roles of DNA Demethylases in Triple-Negative Breast Cancer.

Authors:  Shoghag Panjarian; Jean-Pierre J Issa
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-29

8.  Systematic Analysis of Coronavirus Disease 2019 (COVID-19) Receptor ACE2 in Malignant Tumors: Pan-Cancer Analysis.

Authors:  Jukun Song; Jing Han; Feng Liu; Xianlin Chen; Shenqi Qian; Yadong Wang; Zhenyu Jia; Xiaofeng Duan; Xiangyan Zhang; Jianguo Zhu
Journal:  Front Mol Biosci       Date:  2020-10-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.